Suppression of teratocarcinoma growth by soluble TRAIL gene expression driven by the progression-elevated gene-3 promoter

Cancer Biology and Therapy

Volumn 8, Issue 15, 2009, Pages

  Jiang, Xiang Long ^a   Du, Li Li ^a   Yang, Sheng ^a   Chen, Lian Sheng ^a   Lu, Guang Xiu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; DR4; DR5; EC; rPEG; sTRAIL; Teratocarcinoma

Indexed keywords

1,2 DIOLEOYLOXY 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; CELL CYCLE PROTEIN; CHOLESTEROL; DIFFERENTIATION ANTIGEN; DRUG CARRIER; HYBRID PROTEIN; MONOUNSATURATED FATTY ACID; MYD116 PROTEIN, RAT; ONCOPROTEIN; PEPTIDE FRAGMENT; PPP1R15A PROTEIN, HUMAN; QUATERNARY AMMONIUM DERIVATIVE; RECOMBINANT DNA; SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND (114 281), RAT; SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (114-281), RAT; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; DRUG SCREENING; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; MOUSE; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROMOTER REGION; RAT; SIMIAN VIRUS 40; TERATOCARCINOMA;

ANIMALS; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CELL CYCLE PROTEINS; CHOLESTEROL; DNA, RECOMBINANT; DRUG CARRIERS; FATTY ACIDS, MONOUNSATURATED; GENE THERAPY; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; QUATERNARY AMMONIUM COMPOUNDS; RATS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; SIMIAN VIRUS 40; TELOMERASE; TERATOCARCINOMA; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349588323     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008; 7:309-313
2. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15:504-514 (Pubitemid 351267301)
3. Pal R, Ravindran G. Assessment of pluripotency and multilineage differentiation potential of NTERA-2 cells as a model for studying human embryonic stem cells. Cell Prolif 2006; 39:585-598 (Pubitemid 44760208)
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-760 (Pubitemid 44949604)
5. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-682 (Pubitemid 26091143)
6. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-12690 (Pubitemid 26175834)
7. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-113
8. Pan G, Ni J, Wei YF, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-818 (Pubitemid 27366732)
9. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baluwin D, et al. A novel receptor for Apo-2/TRAIL contains a truncated death domain. Curr Biol 1997; 7:1003-1006 (Pubitemid 28017080)
10. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-821 (Pubitemid 27366733)
11. Ishii M, Iwai M, Harada Y, Kishida T, Asada H, Mazda O, et al. Soluble TRAIL gene and actinomycin D synergistically suppressed multiple metastasis of TRAIL-resistant colon cancer in the liver. Cancer Lett 2007; 245:134-143 (Pubitemid 44959347)
12. Shi J, Zheng D, Liu YY, Sham MH, Tam P, Farzaneh F, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nued mice. Cancer Res 2005; 65:1687-1692 (Pubitemid 40478593)
13. Su ZZ, Sarkar D, Emdad L, Duigou GJ, Young CSH, Ware J, et al. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. PNAS 2005; 25:1059-1064 (Pubitemid 40170725)
14. Zhou J, Ou-Yang Q, Li J, Zhou XY, Lin G, Lu GX. Human feeder cells support establishment and definitive endoderm differentiation of human embryonic stem cells. Stem cells and development 2008; 17:737-750
15. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer gene ther 2004; 11:740-747 (Pubitemid 39488472)
16. Carbonari M, Cibati M, Fiorili M. Measurement of apoptotic cells in peripheral blood. Cytometry 1995; 22:161-167
17. Shirakawa T, Hamada K, Zhang Z, Okada H, Tagawa M, Kamidono S, et al. Cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expression human bladder cancer cells. Clin Cancer Res 2004; 10:4342-4348 (Pubitemid 38878872)
18. Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I, et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004; 113:1017-1024 (Pubitemid 38544123)
19. Gu J, Kagawa S, Takakura M, Kvo S, Inoue M, Roth JA, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60:5359-5364 (Pubitemid 30761241)
20. Irving J, Wang Z, Powll S, O'S ullivan C, Mok M, Murphy B, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer gene ther 2004; 11:174-185
21. Shav J, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787-791 (Pubitemid 27239490)
22. Shi J, Zheng D, Man K, Fan ST, Xu R. TRAIL: a potential agent for cancer therapy. Curr Mol Med 2003; 3:727-736 (Pubitemid 37536878)
23. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. Apoptosis inducing in normal human hepatocytes by tumor necrosis factor-related apoptosis inducing ligand. Nat Med 2000; 6:564-567 (Pubitemid 30305907)
24. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954-960 (Pubitemid 32756434)
25. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apoz2/TRAIL versions. Nat Med 2001; 7:383-385 (Pubitemid 32298514)
26. Hao C, Song JH, His B, Levis J, Song DK, Petruk KC, et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64:8502-8506 (Pubitemid 39552059)
27. Lee J, Hampl M, Albert P, Fine HA. Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002; 4:312-323 (Pubitemid 34755841)
28. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4:257-266
29. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N, et al. A tumor-targeted and conditionally replication oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9:496-509. (Pubitemid 38578800)
30. Niculescu-Duvaz I, Cooper RG, Stribbling SM, Heyes JA, Metcalfe JA, Springer CJ. Recent developments in gene-directed enzyme prodrug therapy (GDEPARTMENT) for cancer. Curr Opin Mol Ther 1999; 1:480-486 (Pubitemid 29420044)
31. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trails. Expert Opin Biol Ther 2001; 1:525-538 (Pubitemid 33768667)
32. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24:7802-7816 (Pubitemid 41670681)
33. Barzon L, Zanusso M, Colombo F, Palu G. Clinical trails of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther 2006; 13:539-554 (Pubitemid 43756242)
34. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, et al. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary hnman hepatocytes. Cancer Res 2003; 63:2369-2372 (Pubitemid 36605170)
35. Carlisle RC, Briggs SS, Hale AB, Green NK, Fisher KD, Etrych T, et al. Use of synthetic vectors for neutralizing antibody resistant delivery of replicating adenovirus DNA. Gene Ther 2006; 13:1579-1586 (Pubitemid 44688458)